Systematic review on the evaluation criteria of orphan medicines in Central and Eastern European countries

BACKGROUND: In case of orphan drugs applicability of the standard health technology assessment (HTA) process is limited due to scarcity of good clinical and health economic evidence. Financing these premium priced drugs is more controversial in the Central and Eastern European (CEE) region where the...

Descripción completa

Detalles Bibliográficos
Autores principales: Zelei, Tamás, Molnár, Mária J., Szegedi, Márta, Kaló, Zoltán
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4893267/
https://www.ncbi.nlm.nih.gov/pubmed/27259284
http://dx.doi.org/10.1186/s13023-016-0455-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4893267/
https://www.ncbi.nlm.nih.gov/pubmed/27259284
http://dx.doi.org/10.1186/s13023-016-0455-6

Ejemplares similares